Phase III with AnGes MG's gene therapy can't come soon enough for investors
This article was originally published in Scrip
Executive Summary
Investors were unimpressed with an update from AnGes MG on 22 October, pushing shares in the Japanese bioventure down by 3.5% to JPY73,700 ($750) in morning trading in Tokyo as it said final Phase III preparations for its lead therapeutic candidate were progressing but still underway.